环孢素A联合丙种球蛋白治疗重型再生障碍性贫血的效果和安全性

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the efficacy and safety of cyclosporin A combined with γ globulin in the treatment of severe aplastic anemia. Methods Sixty-two patients with severe aplastic anemia admitted to the Department of Hematology, Liaoning Provincial People′s Hospital from January 2018 to December 2019 were selected as the research subjects. They were divided into control group (n=31) and observation group (n=31) by odd/even number method. Patients in the control group were treated with Cyclosporin A, and patients in the observation group were treated with Cyclosporin A combined with γ Globulin. The clinical efficacy, safety, biochemical indexes, helper/inducible T lymphocytes (CD4), helper/inducible T suppressor cells (CD8) and ratio of T helper cells to T suppressor cells (CD4/CD8) between the two groups were compared. Results The total effective rate of observation group was higher than that in the control group, and the difference was statistically significant (P<0.05). The difference of the treatment safety between the two groups was not statistically significant (P>0.05). The levels of the hemoglobin (Hb), red blood cell (RBC), peripheral reticulocyte (RC), white blood cell (WBC), absolute neutrophil count (ANC), platelet (PLT) in the observation group were higher than those in the control group,with statistically significant differences(P<0.05).The levels of CD4 and CD4/CD8 in the observation group were higher than those in the control group, and the differences were statistically significant (P<0.05). The level of CD8 in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05). Conclusion For patients with severe aplastic anemia, combination of Cyclosporine A and γ Globulin can effectively improve the spinal cord′s hematopoietic function and greatly alleviate anemia in a favorable clinical effect. The safety is high during treatment, which is worthy of clinical promotion and application.

Key words： Severe aplastic anemia Cyclosporine A &gamma Globulin Biochemical indicator

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Li-mei

Cite this article:

LI Li-mei. Efficacy and safety of Cyclosporin A combined with γ Globulin in the treatment of severe aplastic anemia[J]. 中国当代医药, 2021, 28(16): 57-59转63.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I16/57

[1]	舒凌.小剂量环孢素联合丙种球蛋白治疗非重型再生障碍性贫血疗效评价[J].临床医药文献电子杂志，2019，6（80）：142，144.
[2]	张红梅，李慧霞，赵丽颖，等.环孢素治疗儿童非重型再生障碍性贫血的疗效分析[J].医药与保健，2019，27（2）：104-105.
[3]	王立峰.儿童获得性重型再生障碍性贫血予不同剂量丙种球蛋白辅助免疫抑制治疗的疗效评价[J].中国医学创新，2020，17（7）：68-71.
[4]	田秋生.兔抗人胸腺细胞免疫球蛋白联合环孢素A 治疗重型再生障碍性贫血的疗效观察[J].中国民康医学，2019，31（10）：48-50.
[5]	程海，王雪，徐开林.艾曲波帕联合环孢素A 治疗极重型再生障碍性贫血一例[J].中华血液学杂志，2019，40（7）：612-612.
[6]	刘佳，李建勇，刘正媛，等.中性粒细胞为0 的成人重型再生障碍性贫血强化免疫抑制治疗研究[J].中国实用内科杂志，2020，40（4）：311-315.
[7]	成晓玲，马洁，陈振萍，等.104 例儿童再生障碍性贫血环孢素A 浓度监测策略的回顾性分析[J].中国医药导报，2018，15（29）：108-111.
[8]	周晨，陈娟，殷鲜鲜.临床护理在慢性再生障碍性贫血患者环孢素A 治疗过程中的应用价值[J].影像研究与医学应用，2018，2（7）：224-225.
[9]	高红秀，王萍，王萌，等.小剂量环孢素A 联合司坦唑醇治疗非重型再生障碍性贫血的疗效观察[J].现代诊断与治疗，2018，29（18）：43-44.
[10]	陈芳菲，郭智玮，张立男，等.52 例非重型再生障碍性贫血患者环孢素A 治疗前后生活质量的变化研究[J].中华血液学杂志，2020，41（10）：806-810.
[11]	王超，薛胜利，李正，等.异基因造血干细胞移植后自身免疫性溶血性贫血一例并文献复习[J].白血病·淋巴瘤，2018，27（4）：228-233，237.
[12]	胡宁.小剂量环孢素A 治疗非重型再生障碍性贫血效果观察[J].中国民康医学，2019，31（16）：53-55.
[13]	周章军，李雯雯，杜艳.环孢素A 联合十一酸睾酮治疗非重型再生障碍性贫血的临床观察[J].当代医学，2018，24（18）：60-63.
[14]	董杰.ATG 联合CsA 治疗重型再生障碍性贫血的临床价值研究[J].中国实用医药，2019，14（12）：127-129.
[15]	吴鸿飞，谢新生，万鼎铭，等.Haplo-HSCT 治疗重型再生障碍性贫血40 例的疗效观察[J].中华器官移植杂志，2019，40（3）：153-157.
[16]	颜小花.环孢素A 联合司坦唑醇治疗慢性再生障碍性贫血的效果[J].河南医学研究，2020，29（10）：1809-1810.
[17]	郭媛媛.养血饮联合环孢素A 治疗再生障碍性贫血临床观察[J].西部中医药，2020，33（7）：121-124.